Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration

Aguiar, 2006, Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesions in rats, Pharmacol. Biochem. Behav., 84, 415, 10.1016/j.pbb.2006.05.027 Anderson, 2006, Neuroprotection in Parkinson models varies with toxin administration protocol, Eur. J. NeuroSci., 24, 3174, 10.1111/j.1460-9568.2006.05192.x Ascherio, 2001, Prospective study of caffeine consumption and risk of Parkinson's disease in men and women, Ann. Neurol., 50, 56, 10.1002/ana.1052 Ascherio, 2006, Pesticide exposure and risk for Parkinson's disease, Ann. Neurol., 60, 197, 10.1002/ana.20904 Aumann, 2008, SK channel function regulates the dopamine phenotype of neurons in the substantia nigra pars compacta, Exp. Neurol., 213, 419, 10.1016/j.expneurol.2008.07.005 Baldi, 2003, Neurodegenerative diseases and exposure to pesticides in the elderly, Am. J. Epidemiol., 157, 409, 10.1093/aje/kwf216 Bove, 2005, Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways, Exp. Brain Res., 165, 362, 10.1007/s00221-005-2302-1 Brooks, 1999, Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss, Brain Res., 823, 1, 10.1016/S0006-8993(98)01192-5 Carta, 2009, Inactivation of neuronal forebrain A2A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease, J. Neurochem., 111, 1478, 10.1111/j.1471-4159.2009.06425.x Cavalieri, 1966 Chade, 2006, Non genetic causes of Parkinson's disease, J. Neural. Transm. Suppl., 70, 147 Chan, 1997, (+) MK-801 does not prevent MPTP-induced loss of nigral neurons in mice, J. Pharmacol. Exp. Ther., 280, 439 Chen, 2001, Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease, J. Neurosci., 21, 1 Costello, 2009, Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California, Am. J. Epidemiol., 169, 919, 10.1093/aje/kwp006 Datta, 1996, Accumulation of tyrosine hydroxylase messenger RNA molecules in the rat mesencephalon by chronic caffeine treatment, Neurosci. Lett., 230, 77, 10.1016/S0304-3940(96)13213-4 Ferraz, 1988, Chronic exposure to the fungicide maneb may produce symptoms and signs of CNS manganese intoxication, Neurology, 38, 550, 10.1212/WNL.38.4.550 Fornai, 2005, Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin–proteasome system and alpha-synuclein, Proc. Natl. Acad. Sci. U. S. A., 102, 3413, 10.1073/pnas.0409713102 Giovanni, 1991, Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine administration to several strains of mice, J. Pharmacol. Exp. Ther., 257, 691 Heikkila, 1985, Differential neurotoxicity of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in Swiss–Webster mice from different sources, Eur. J. Pharmacol., 117, 131, 10.1016/0014-2999(85)90482-0 Hertzman, 1990, Parkinson's disease: a case–control study of occupational and environmental risk factors, Am. J. Ind. Med., 17, 349, 10.1002/ajim.4700170307 Hung, 2007, Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?, Curr. Opin. Neurol., 20, 477, 10.1097/WCO.0b013e32826388d6 Ikeda, 2002, Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease, J. Neurochem., 80, 262, 10.1046/j.0022-3042.2001.00694.x Joghataie, 2004, Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence, Parkinsonism Relat. Disord., 10, 465, 10.1016/j.parkreldis.2004.06.004 Liou, 1997, Environmental risk factors and Parkinson's disease: a case control study in Taiwan, Neurology, 48, 1583, 10.1212/WNL.48.6.1583 McCarthy, 2004, Paraquat induces oxidative stress and neuronal cell death: neuroprotection by water-soluble coenzyme Q10, Toxicol. Appl. Pharmacol., 201, 21, 10.1016/j.taap.2004.04.019 McCormack, 2002, Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat, Neurobiol. Dis., 10, 119, 10.1006/nbdi.2002.0507 Meco, 1994, Parkinsonism after chronic exposure to the fungicide maneb (manganese ethylene-bisdithiocarbamate, Scand. J. Work Environ. Health, 20, 301, 10.5271/sjweh.1394 Melvin, 2009, Quantitative caveats of standard immunohistochemical procedures: implications for optical disector-based designs, J. Histochem. Cytochem., 10, 1 Mizuno, 1999, Genetic and environmental factors in the pathogenesis of Parkinson's disease, Adv. Neurol., 80, 171 Oztas, 2002, Caffeine attenuates MPTP-induced loss of dopaminergic neurons in substantia nigra in mice, Soc. Neurosci. Petrovitch, 2002, Plantation work and risk of Parkinson disease in a population-based longitudinal study, Arch. Neurol., 59, 1787, 10.1001/archneur.59.11.1787 Pierri, 2005, KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse, Neuropharmacology, 48, 517, 10.1016/j.neuropharm.2004.11.009 Popoli, 1995, Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in the rat striatum, Eur. J. Pharmacol., 287, 215, 10.1016/0014-2999(95)00679-6 Prasad, 2007, Prolonged toxicokinetics and toxicodynamics of paraquat in mouse brain, Environ. Health Perspect., 115, 1448, 10.1289/ehp.9932 Ravina, 2003, Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment, Neurology, 60, 1234, 10.1212/01.WNL.0000058760.13152.1A Saint-Pierre, 2006, Temporal effects of paraquat/maneb on microglial activation and dopamine neuronal loss in older rats, J. Neurochem., 98, 760, 10.1111/j.1471-4159.2006.03923.x Satomi, 2004, Gene expression of the lung following paraquat administration in rats using DNA microarray, J. Toxicol. Sci., 29, 91, 10.2131/jts.29.91 Suchowersky, 2006, Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology, 66, 976, 10.1212/01.wnl.0000206363.57955.1b Tanner, 2009, Occupation and risk of parkinsonism: a multicenter case control study, Arch. Neurol., 66, 1106, 10.1001/archneurol.2009.195 Tanner, 1987, Environmental factors in the etiology of Parkinson's disease, Can. J. Neurol. Sci., 14, 419, 10.1017/S0317167100037835 Thiruchelvam, 2000, Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease?, Brain Res., 873, 225, 10.1016/S0006-8993(00)02496-3 Thiruchelvam, 2000, The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease, J. Neurosci., 20, 9207, 10.1523/JNEUROSCI.20-24-09207.2000 United States Geographic Service, 1998 Warner, 2003, Genetic and environmental factors in the cause of Parkinson's disease, Ann. Neurol., 53, 16, 10.1002/ana.10487 West, 1993, Unbiased stereological estimation of the total number of neurons in the subdivision of the rat hippocampus using the optical fractionators, Anat. Record, 231, 482, 10.1002/ar.1092310411 Wirdefeldt, 2004, No evidence for heritability of Parkinson's disease in Swedish twins, Neurology, 63, 305, 10.1212/01.WNL.0000129841.30587.9D Xu, 2005, Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease, Pharmacol. Ther., 105, 267, 10.1016/j.pharmthera.2004.10.007 Xu, 2006, Neuroprotection by caffeine in the MPTP model of Parkinson's disease: the role of adenosine A2A receptor, Soc. Neurosci. Yu, 2008, Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms, Ann. Neurol., 63, 338, 10.1002/ana.21313